Copaxone Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Alerts
• Clinical Trials

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: Glatiramer acetate (GA);   Other: PlaceboSponsor:   Teva Pharmaceutical IndustriesActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2010 Category: Research Source Type: clinical trials

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: Glatiramer acetate (GA);   Other: PlaceboSponsor:   Teva Pharmaceutical IndustriesActive, not recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 10, 2010 Category: Research Source Type: clinical trials

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: BG00002 (natalizumab);   Drug: interferon beta-1a;   Drug: glatiramer acetateSponsors:   Biogen Idec;   Elan PharmaceuticalsTerminated - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2010 Category: Research Source Type: clinical trials

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: BG00002 (natalizumab);   Drug: interferon beta-1a;   Drug: glatiramer acetateSponsors:   Biogen Idec;   Elan PharmaceuticalsTerminated - verified July 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2010 Category: Research Source Type: clinical trials

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
Condition:   Relapsing Remitting Multiple SclerosisInterventions:   Drug: BG00002 (natalizumab);   Drug: interferon beta-1a;   Drug: glatiramer acetateSponsors:   Biogen Idec;   Elan PharmaceuticalsTerminated - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2010 Category: Research Source Type: clinical trials